Chronic Myelomonocytic Leukemia (CMML) is a myeloid malignancy that shares clinical and pathological features of both myelodysplastic syndromes and myeloproliferative neoplasms.
The most important points regarding CMML are:
- Leukemic Transformation: CMML is frequently associated with the development of secondary AML, which is generally considered unfavorable and often incurable with conventional “7+3” chemotherapy.
- Targeted Treatment: If a patient aged 60–75 develops AML following a history of CMML, CPX-351 (liposomal cytarabine / daunorubicin) is a Category 1 recommendation because it demonstrated superior survival in this specific population.
- Risk Categorization: In clinical treatment algorithms, prior CMML is used to define “secondary AML,” grouping it with therapy-related AML and AML with myelodysplasia-related changes.
Synonyms
CMML